Influence of hypoxia/ischemia on cerebrovascular responses to oxytocin in piglets

J Vasc Res. 1997 Jul-Aug;34(4):312-20. doi: 10.1159/000159239.

Abstract

We examined the effects of hypoxic/ischemic stress on cerebral arteriolar responses to oxytocin in anesthetized piglets. Pial arteriolar diameters were measured using a cranial window and intravital microscopy. First, we evaluated arteriolar responses to topical application of oxytocin during normoxic conditions. We then determined whether 5-10 min of arterial hypoxia, ischemia, or asphyxia alters oxytocin-induced responses. Arterial hypoxia was produced by inhalation of 7.5% O2-92.5% N2 for 10 min. Ischemia was achieved by increasing intracranial pressure for 10 min. Asphyxia was achieved by turning off the ventilator for 5 min. During normoxic conditions, oxytocin dilated pial arterioles by 9 +/- 1% at 10(-8) and by 16 +/- 1% at 10(-6) mol/l (n = 47, p < 0.05). Arteriolar responses to oxytocin did not change with repeated applications (n = 10). Following hypoxia, dilator effect of oxytocin was not changed at 10(-8) (8 +/- 2%) but it was reduced at 10(-6) mol/l (7 +/- 2%; p < 0.05, n = 8). After asphyxia or ischemia, oxytocin did not dilate arterioles at 10(-8) mol/l, whereas 10(-6) mol/l resulted in a mild vasoconstriction (-4 +/- 3 to -6 +/- 4%, n = 6 and 8). Topically applied superoxide dismutase did not preserve arteriolar responses to oxytocin after asphyxia although the arterioles did not constrict to 10(-6) mol/l oxytocin (n = 5). Dilatation of cerebral arterioles in response to oxytocin was reversed to constriction by N(omega)-nitro-L-arginine methyl ester (L-NAME) (15 mg/kg, i.v.; n = 5) and by endothelial impairment by intra-arterial infusion of phorbol ester (10[-5] mol/l; n = 5). We conclude that the absence of pial arteriolar dilation to oxytocin after ischemia and asphyxia indicates endothelial dysfunction which may be involved in the pathology of perinatal brain injury.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
  • Animals
  • Animals, Newborn
  • Brain / blood supply*
  • Brain Ischemia / physiopathology*
  • Cerebrovascular Circulation / drug effects*
  • Female
  • Hypoxia / physiopathology*
  • Male
  • Nitric Oxide / physiology
  • Oxytocin / pharmacology*
  • Potassium Channels / physiology
  • Prostaglandin Endoperoxides, Synthetic / pharmacology
  • Superoxides / metabolism
  • Swine
  • Thromboxane A2 / analogs & derivatives
  • Thromboxane A2 / pharmacology
  • Vasoconstriction
  • Vasoconstrictor Agents / pharmacology
  • Vasodilation

Substances

  • Potassium Channels
  • Prostaglandin Endoperoxides, Synthetic
  • Vasoconstrictor Agents
  • Superoxides
  • Nitric Oxide
  • Oxytocin
  • Thromboxane A2
  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid